Moderna, Republic of Korea Govt ink pact for 40 million doses of COVID-19 vaccine

Published On 2021-01-02 04:30 GMT   |   Update On 2021-01-05 07:24 GMT

Cambridge: Pharma major, Moderna, Inc., has confirmed that the Company has entered into a supply agreement with the government of the Republic of Korea to provide 40 million doses of the Moderna COVID-19 Vaccine to support the government's aim of providing vaccines to the public as soon as possible. Under the terms of the proposed agreement, deliveries would begin in May 2021. The...

Login or Register to read the full article

Cambridge: Pharma major,  Moderna, Inc., has confirmed that the Company has entered into a supply agreement with the government of the Republic of Korea to provide 40 million doses of the Moderna COVID-19 Vaccine to support the government's aim of providing vaccines to the public as soon as possible.

Under the terms of the proposed agreement, deliveries would begin in May 2021. The Moderna COVID-19 Vaccine is not currently approved for use in South Korea, and the Company will work with regulators to pursue the necessary approvals prior to distribution.

"We thank the Republic of Korea for partnering with us to bring the Moderna COVID-19 Vaccine to South Korea. The government has moved very swiftly to get this done in the face of the pandemic. We believe this supply agreement is an important step towards building a long-lasting future collaboration between Moderna and the Republic of Korea," said Stéphane Bancel , Chief Executive Officer of Moderna. "We look forward to continuing discussions with government officials and to building a stronger scientific and clinical presence of Moderna in South Korea."

Read also: Moderna COVID-19 vaccine trial show 94.1 percent efficacy: NEJM study

Moderna is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune and inflammatory diseases, independently and with strategic collaborators. 

The company COVID-19 Vaccine has not been approved or licensed by U.S. Food and Drug Administration (FDA), but FDA has authorized the vaccine for emergency use in individuals 18 years of age and older.

Tags:    

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News